Literature DB >> 17375274

[Primary CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the literature and case report].

F Kästner1, W Paulus, M Deckert, P Schlegel, S Evers, I W Husstedt.   

Abstract

We present a 31-year-old female patient with primary non-Hodgkin's lymphoma of the CNS after immunosuppressive therapy. Colitis ulcerosa had been diagnosed 2 years previously. Prophylactic therapy with azathioprine over 9 months was stopped after the development of listeria meningitis which was treated successfully with antibiotics. At this time native CCT was normal. Three months later the patient developed an epileptic seizure and multiple cerebral lesions were detected in CCT and MRI. Although antibiotic therapy was started, the cerebral lesions showed no regression. Stereotactic biopsy revealed immunochemical and histologic high-grade malignant B cell lymphoma. The risk of primary CNS lymphoma under azathioprine treatment for an autoimmune disease with a possible congenital immunodeficiency is presented and the literature is reviewed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17375274     DOI: 10.1007/s00115-007-2255-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  46 in total

1.  [Diagnosis of an initial infratentorial central nervous system B-cell lymphoma during prolonged cortisone medication].

Authors:  A Buss; A Assmus; J Weidemann; B Sellhaus; J Lorenzen; F Block
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

2.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

3.  Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis.

Authors:  R Hohlfeld; M Michels; K Heininger; U Besinger; K V Toyka
Journal:  Neurology       Date:  1988-02       Impact factor: 9.910

4.  Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.

Authors:  Gerald A Dayharsh; Edward V Loftus; William J Sandborn; William J Tremaine; Alan R Zinsmeister; Thomas E Witzig; William R Macon; Lawrence J Burgart
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

5.  Epidemiology of primary CNS lymphoma.

Authors:  M Schabet
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

6.  Inflammatory bowel disease is not associated with an increased risk of lymphoma.

Authors:  J D Lewis; W B Bilker; C Brensinger; J J Deren; D J Vaughn; B L Strom
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

Review 7.  Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.

Authors:  Marla C Dubinsky
Journal:  Clin Gastroenterol Hepatol       Date:  2004-09       Impact factor: 11.382

8.  Immunoblastic sarcoma (histiocytic lymphoma) of the brain with B cell markers. Case report.

Authors:  C Varadachari; M Palutke; A R Climie; R W Weise; J L Chason
Journal:  J Neurosurg       Date:  1978-12       Impact factor: 5.115

9.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Authors:  Y Bouhnik; M Lémann; J Y Mary; G Scemama; R Taï; C Matuchansky; R Modigliani; J C Rambaud
Journal:  Lancet       Date:  1996-01-27       Impact factor: 79.321

10.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.

Authors:  W R Connell; M A Kamm; M Dickson; A M Balkwill; J K Ritchie; J E Lennard-Jones
Journal:  Lancet       Date:  1994-05-21       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.